The horizontal bar graph provides FDA actual and preliminary “on-time” performance on two actions related to manufacturing supplements to NDAs and BLAs. Both on-time goals are at 90 percent of actions. Performance results for FY 2004 and preliminary performance results for FY 2005 show that FDA is exceeding both goals.